Main navigation
You are here
- Home
SEROQUEL XR in schizophrenia
Efficacy and Tolerability
The following pages provide an overview of the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR; SEROQUEL XR) in patients with schizophrenia.
The immediate release formulation of SEROQUEL™ is administered twice daily for the treatment of schizophrenia. A once-daily extended release formulation of SEROQUEL (SEROQUEL XR) has been developed to provide patients and physicians with a more convenient dosing regimen that reaches the recommended dose range in 2 days.
Please consult your local prescribing information before prescribing SEROQUEL or SEROQUEL XR.
References
1. Kahn RS et al. J Clin Psychiatry 2007; 68: 832-842.
2. Möller H-J et al. International Clinical Psychopharmacology 2008; 23: 95-105.
3. Ganesan S et al. Curr Med Res Opin 2008; 24: 21-32.
4. Peuskens J et al. Psychiatry (Edgemont) 2007; 4: 34-50.